Cagrilintide Research Guide: Amylin Analog, GLP-1 Synergy & Metabolic Studies

Cagrilintide is a long-acting synthetic analog of human amylin, a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. Developed by Novo Nordisk, cagrilintide was engineered for once-weekly subcutaneous administration by combining the amylin receptor agonist pharmacology of pramlintide with albumin-binding fatty acid conjugation to extend half-life from minutes to approximately 7–8 days. In clinical development, cagrilintide has been studied both as a standalone obesity treatment and, most notably, in combination with the GLP-1 receptor agonist GLP-1S (as the dual combination therapy CagriSema), representing a novel dual-hormone approach to energy homeostasis research with weight loss efficacy exceeding either component alone.

For research use only. Not intended for human or veterinary use.

Background: Amylin in Energy Homeostasis

Amylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells in response to nutrient intake. First characterized in the late 1980s, amylin was initially notorious as the primary component of islet amyloid deposits in type 2 diabetes, but subsequent research established it as a functional metabolic hormone with important roles in meal-related satiety, gastric emptying, and glucagon suppression.

Amylin acts through amylin receptors (AMY receptors), heterodimers of calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMPs 1, 2, or 3). AMY receptors are highly expressed in the area postrema (AP) and nucleus tractus solitarius (NTS) of the brainstem, satiety centers that receive vagal afferent input from the gut. Beta cell secretion of amylin is proportional to meal size, providing a “portion signal” that limits meal size through central satiety mechanisms. Amylin-deficient or amylin-resistant states are associated with impaired satiety and hyperphagia.

Structure and Key Properties

• Base structure: Human amylin analog with multiple amino acid substitutions to prevent aggregation (a limitation of native amylin and pramlintide) and enable albumin binding
• Fatty acid conjugation: C18 fatty diacid linked via a hydrophilic linker to enable albumin binding, the same half-life extension strategy used in GLP-1S and insulin degludec
• Half-life: Approximately 7–8 days (enabling once-weekly dosing)
• Receptor: AMY1, AMY2, AMY3 receptors (CTR + RAMP heterodimers); also calcitonin receptor
• Clinical development: Phase III trials as CagriSema (cagrilintide + GLP-1S 2.4 mg) for obesity and type 2 diabetes

Mechanism of Action

Brainstem Satiety Signaling

Cagrilintide activates AMY receptors in the area postrema and NTS, brainstem regions outside the blood-brain barrier that integrate peripheral metabolic signals. AMY receptor activation in these nuclei reduces meal size through activation of cAMP/PKA signaling in satiety neurons that project to hypothalamic energy balance circuits. Unlike GLP-1 receptor agonists, which primarily act on hypothalamic GLP-1R and vagal GLP-1R, amylin analogs predominantly signal through brainstem circuits, providing mechanistically distinct and complementary satiety pathways.

Gastric Emptying Delay

Amylin/cagrilintide delays gastric emptying, slowing the transit of ingested food from the stomach to the small intestine. This delayed gastric emptying contributes to satiety (mechanical distension sustains gastric fullness longer), blunts postprandial glucose excursions (by slowing carbohydrate absorption), and reduces appetite through sustained gastric volume. This mechanism is shared with GLP-1 receptor agonists, though the relative contribution and magnitude differ between the two receptor systems.

Glucagon Suppression

Amylin suppresses postprandial glucagon secretion from pancreatic alpha cells, complementing insulin’s glucose-lowering action by preventing the hyperglucagonemia that would otherwise partially counteract insulin-mediated glucose disposal. This glucagon-suppressing action contributes to improved postprandial glucose control and has been characterized in both native amylin and pramlintide research. Cagrilintide’s longer half-life provides continuous (rather than meal-phasic) glucagon suppression, with implications for basal glucose homeostasis beyond the immediate postprandial window.

GLP-1 Synergy: Complementary Receptor Mechanisms

The scientific rationale for cagrilintide/GLP-1S combination therapy rests on mechanistic complementarity. GLP-1 receptor agonists (GLP-1S) act primarily through hypothalamic GLP-1R and vagal GLP-1R to reduce appetite, slow gastric emptying, and stimulate insulin secretion. Amylin analogs (cagrilintide) act primarily through brainstem AMY receptors, delay gastric emptying via a separate pathway, and suppress glucagon. Animal studies demonstrated additive to synergistic weight loss when amylin and GLP-1 pathways were co-activated, a key preclinical finding supporting the clinical combination program. The CNS circuits mediating these effects partially overlap (both activate energy balance circuits in the hypothalamus and brainstem) but involve distinct receptor populations, providing additive efficacy.

Key Research Findings

CagriSema Phase II (SCALE-CAGRI)

Lau et al. (2021) published Phase II CagriSema data in The Lancet, reporting mean weight loss of 17.1% from baseline at 32 weeks in the highest-dose group, significantly exceeding the ~10% achieved with GLP-1S 1.0 mg alone or ~8% with cagrilintide alone in the same trial. This additive efficacy confirmed the complementary mechanism hypothesis and drove the Phase III REDEFINE program. The trial also demonstrated favorable metabolic effects: improvements in HbA1c, fasting glucose, blood pressure, and waist circumference beyond either monotherapy.

Cagrilintide Monotherapy Dose-Finding

Separate Phase II monotherapy studies characterized cagrilintide’s standalone weight loss profile and dose-response relationship. Friedrichsen et al. (2021) reported dose-dependent weight loss of up to 10.8% at 26 weeks with once-weekly cagrilintide 4.5 mg in overweight/obese subjects, comparable to GLP-1 receptor agonist monotherapy and confirming meaningful standalone efficacy through the amylin mechanism alone.

Type 2 Diabetes Models

In type 2 diabetes research models, the combination of amylin receptor agonism with GLP-1 receptor agonism addresses multiple pathophysiological defects simultaneously: impaired postprandial insulin secretion (GLP-1R), postprandial hyperglucagonemia (amylin), delayed gastric emptying for glucose absorption blunting (both), and central hyperphagia (both via complementary brainstem/hypothalamic circuits). Preclinical studies in diabetic rodent models confirmed superior glycemic control and weight reduction with the combination versus either component, providing mechanistic grounding for the ongoing REDEFINE-2 trial in T2D patients.

Reconstitution Protocol

Cagrilintide is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial; do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless; do not shake or vortex
• Refrigerate reconstituted solution at 2–8°C; stable approximately 3–4 weeks; protect from light
• Do not freeze reconstituted solution; lyophilized powder may be stored at -20°C

References

• Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., … & Blundell, J. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10300), 2160–2172.
• Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of GLP-1S 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754–762.
• Lutz, T. A. (2010). The role of amylin in the control of energy homeostasis. American Journal of Physiology, Regulatory, Integrative and Comparative Physiology, 298(6), R1475–R1484.
• Bhatt, D. L., Aroda, V. R., Bhatt, D. L., & Nauck, M. A. (2022). The REDEFINE clinical trial program for cagrilintide/GLP-1S. Cardiovascular Diabetology, 21, 265.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade Cagrilintide Available

Exceed Enhancement offers research-grade Cagrilintide for qualified research applications. View product specifications and ordering information →